With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Subscribe To Our Newsletter & Stay Updated
